Options
Dra. Gerli-Candia, Lorena
Nombre de publicación
Dra. Gerli-Candia, Lorena
Nombre completo
Gerli Candia, Lorena Andrea
Facultad
Email
loregerli@ucsc.cl
ORCID
Scopus Author ID
6506865225
Researcher ID
GLU-4473-2022
3 results
Research Outputs
Now showing 1 - 3 of 3
- PublicationIdentification of novel coumarin based compounds as potential inhibitors of the 3-Chymotrypsin-like main protease of Sars-Cov-2 Using Dft, molecular docking and molecular dynamics simulation studies(Journal of the Chilean Chemical Society, 2022)
;Cardona, Wilson ;Mendoza Huizar, L.H.; ;Salgado Moran, G.Abdizadeh, ToobaSARS-CoV-2 is the pandemic disease-causing agent COVID-19 with high infection rates. Despite the progress made in vaccine development, there is an urgent need for the identification of antiviral compounds that can tackle better the different phases of SARS-CoV-2. The main protease (Mpro or 3CLpro) of SARS-CoV-2 has a crucial role in viral replication and transcription. In this study, an in silico method was executed to elucidate the inhibitory potential of the synthesized 6-tert-octyl and 6-8-ditert-butyl coumarin compounds against the major protease of SARS-CoV-2 by comprehensive molecular docking and density functional theory (DFT), ADMET properties and molecular dynamics simulation approaches. Both compounds shown favorable interactions with the 3CLpro of the virus. From DFT calculations, HOMO-LUMO values and global descriptors indicated promising results for these compounds. Furthermore, molecular dynamics studies revealed that these ligand-receptor complexes remain stable during simulations and both compounds showed considerably high binding affinity to the main SARS-CoV-2 protease. The results of the study suggest that the coumarin compounds 6-tert-octyl and 6-8-ditert-butyl could be considered as promising scaffolds for the development of potential COVID-19 inhibitors after further studies. - PublicationA computational predicting of possible inhibitors of the main SARS-CoV-2 protease found in Algerian herbal medicines(Universidad Nacional de Colombia, 2022)
; ;Yabrir, Benalia ;Belhassan, Assia ;Salgado-Moran, Guillermo ;Lakhlifi, TaharBouachrine, MohammedCOVID-19 is a zoonotic viral disease caused by the SARS-CoV-2 virus. Its abrupt outbreak has caused a tremendous challenge to public health systems due to the rapid spread of the virus. In this sense, a great deal of work has been focused on finding substances from herbal plants to be used against this virus. In order to investigate the molecular interactions between natural metabolites from Algerian herbal plants and the SARS-CoV-2 protease Mpro, computational docking and molecular dynamics were used, also the drug likeness degree and in silico ADMET prediction were carried out in this study. warfarin and catalponol preferentially binds to a pocket of the SARS-Cov-2 Mpro active site that is made up of residues His 41 to Glu 166 and Leu 27 to His 163 with a relatively low binding energy of -7.1 and -6.6 kcal/mol respectively. Dynamic molecular assay further established that only warfarin managed to stay in the active site. The results suggest that warfarin may be an interesting candidate for development as a medical treatment of COVID-19 and more research is proposed, without disregarding its toxicity which deserves to be well studied. - PublicationMolecular docking and molecular dynamics studies of SARS-CoV-2 inhibitors: Crocin, digitoxigenin, beta eudesmol and favipiravir: comparative study(AMG Transcend Association, 2022)
;Mora, José R. ;Cuesta, Sebastián A. ;Belhassan, Assia ;Salgado Morán, G. ;Lakhlifi, Tahar ;Bouachrine, Mohammed ;Peña F., Carlos; Mendoza Huizar, Luis H.In this study, Crocin, Digitoxigenin, Beta-Eudesmol, and Favipiravir were docked in the active site of SARS-CoV-2 main protease (PDB code: 6LU7). The docking study was followed by Molecular Dynamics simulation. The result indicates that Crocin and Digitoxigenin are the structures with the best affinity in the studied enzyme's binding site. Still, Molecular Dynamics simulation showed that Digitoxigenin is the molecule that fits better in the active site of the main protease. Therefore, this molecule could have a more potent antiviral treatment of COVID-19 than the other three studied compounds.